Zug, Switzerland | July 20, 2026
Galderma announced the expansion of its Alastin® regenerative skincare brand across the Japan and Asia Pacific (JPAC) region, marking another major step in its global dermatology growth strategy. Following recent launches in China and Australia, the company has introduced Alastin in Taiwan, with launches planned in Japan, Singapore, and South Korea later this year. The expansion reflects Galderma’s long-term commitment to regenerative skincare innovation in one of the world’s fastest-growing medical aesthetics markets, where increasing demand for science-based skincare, minimally invasive aesthetic procedures, and skin quality treatments continues to drive adoption. The company aims to strengthen its leadership by offering clinically validated skincare solutions that complement professional aesthetic treatments while supporting long-term skin health.
Alastin Portfolio Brings Advanced Regenerative Science to JPAC
Alastin has become one of the most clinically researched professional skincare brands, supported by more than 60 international dermatology publications and over 25 granted patents. Its product portfolio is designed to support skin regeneration before and after aesthetic procedures while improving daily skin health through advanced regenerative technology. Several products feature proprietary TriHex Technology®, a peptide-based platform that helps remove aged collagen and elastin while simultaneously stimulating the production of new healthy collagen and elastin, promoting stronger, healthier-looking skin. The newly introduced Restorative Skin Complex with TriHex+™ further enhances this regenerative approach by supporting the skin’s natural production of high molecular weight hyaluronic acid, improving hydration, elasticity, and long-term skin resilience. The JPAC portfolio includes procedure support products, daily regenerative treatments, targeted antioxidant and brightening serums, and advanced moisturizers, providing comprehensive skincare solutions throughout the aesthetic treatment journey.
Growing Demand for Medical Aesthetic Skincare Drives Expansion
The Japan and Asia Pacific region continues to experience strong growth in injectable aesthetics and dermatological skincare, driven by increasing consumer awareness of preventive skincare, skin longevity, and non-invasive cosmetic treatments. Patients increasingly seek skincare products that enhance treatment outcomes while reducing recovery time following procedures such as injectables, laser therapies, and energy-based devices. According to Galderma, Alastin addresses these evolving needs by supporting skin readiness, post-procedure recovery, collagen remodeling, hydration, and overall skin quality. Dermatologists in Japan highlighted that modern patients now expect skincare solutions capable of improving skin function and regeneration, rather than simply providing temporary hydration. By integrating scientifically validated regenerative skincare with professional dermatology and aesthetic treatments, Galderma is positioning Alastin as a comprehensive solution for both healthcare professionals and patients across the region.
Advertisement
Galderma Strengthens Leadership in Global Dermatology and Aesthetics
The launch further reinforces Galderma’s strategy to expand its premium dermatology portfolio while capitalizing on growing global demand for regenerative skincare solutions. As a leading dermatology company operating in approximately 90 countries, Galderma continues investing in innovations that combine clinical science, peptide technology, and dermatological expertise. The company believes Alastin complements its broader Injectable Aesthetics portfolio by providing integrated skincare solutions before, during, and after cosmetic procedures. Beyond procedural skincare, the portfolio also addresses emerging trends including healthy skin aging, menopause-related skin changes, medication-driven weight loss, and long-term skin maintenance. With continued expansion across Asia Pacific, Galderma aims to broaden patient access to premium regenerative skincare while supporting healthcare professionals with evidence-based products designed to improve visible treatment outcomes and long-term skin health.
Source: Galderma press release
